Literature DB >> 12445468

DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury.

Andrew M Schumacher1, Anastasia V Velentza, D Martin Watterson, Mark S Wainwright.   

Abstract

Death-associated protein kinase (DAPK) is a pro-apoptotic, calmodulin (CaM)-regulated protein kinase whose mRNA levels increase following cerebral ischemia. However, the relationship between DAPK catalytic activity and cerebral ischemia is not known. This knowledge is critical as DAPK function is dependent on the catalytic activity of its kinase domain. Consequently, we examined DAPK catalytic activity in a rat model of neonatal cerebral hypoxia-ischemia (HI). An increase in DAPK specific activity was found in homogenates of the hippocampus from the injured right hemisphere, compared to the uninjured left hemisphere, 7 days after injury. The results raised the possibility that an upregulation of DAPK activity might be associated with the recovery phase of HI, during which neuronal repair and differentiation are initiated. Therefore, we examined the change of DAPK in an experimentally tractable cell culture model of neuronal differentiation. We found that DAPK catalytic activity and protein levels increase after nerve growth factor (NGF)-induced differentiation of rat PC12 cells. These results suggest that DAPK may have a previously unappreciated role in neuronal development or recovery from injury, and that potential future therapies targeting DAPK should consider a restricted time window.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445468     DOI: 10.1016/s1570-9639(02)00453-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific.

Authors:  Dayton J Goodell; Vincent Zaegel; Steven J Coultrap; Johannes W Hell; K Ulrich Bayer
Journal:  Cell Rep       Date:  2017-06-13       Impact factor: 9.423

Review 2.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

3.  Site-directed mutagenesis of the glycine-rich loop of death associated protein kinase (DAPK) identifies it as a key structure for catalytic activity.

Authors:  Laurie K McNamara; Joseph S Brunzelle; James P Schavocky; D Martin Watterson; Valerie Grum-Tokars
Journal:  Biochim Biophys Acta       Date:  2010-11-29

4.  Death-associated protein kinase-mediated cell death modulated by interaction with DANGER.

Authors:  Bingnan N Kang; Abdullah S Ahmad; Sofiyan Saleem; Randen L Patterson; Lynda Hester; Sylvain Doré; Solomon H Snyder
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

5.  Attenuation of EPO-dependent erythroblast formation by death-associated protein kinase-2.

Authors:  Jing Fang; Madhu Menon; Diya Zhang; Bruce Torbett; Leif Oxburgh; Mario Tschan; Estelle Houde; Don M Wojchowski
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

6.  The role of DAPK-BimEL pathway in neuronal death induced by oxygen-glucose deprivation.

Authors:  C He; A R Stroink; C X Wang
Journal:  Neuroscience       Date:  2013-11-21       Impact factor: 3.590

7.  Antisense depletion of death-associated protein kinase promotes apoptosis.

Authors:  Yijun Jin; Patricia J Gallagher
Journal:  J Biol Chem       Date:  2003-10-06       Impact factor: 5.157

8.  A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells.

Authors:  Loren E Glover; Naoki Tajiri; Nathan L Weinbren; Hiroto Ishikawa; Kazutaka Shinozuka; Yuji Kaneko; D Martin Watterson; Cesar V Borlongan
Journal:  Transl Stroke Res       Date:  2011-11-18       Impact factor: 6.829

9.  Structural insight into nucleotide recognition by human death-associated protein kinase.

Authors:  Laurie K McNamara; D Martin Watterson; Joseph S Brunzelle
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-02-20

10.  Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression.

Authors:  D Martin Watterson; Anastasia V Velentza; Magdalena Zasadzki; Jeffrey M Craft; Jacques Haiech; Linda J Van Eldik
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.